3.270 articles found

A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease.

Bowen S, Blacker D, Prettyman R.

J Parkinsons Dis · 2025-02-06

DOI: 10.1177/1877718x251315651PMID: 39973485

Relationship Between Morning Blood Pressure Surges and Peripheral Inflammatory Biomarkers in Parkinson's Disease.

Sari US, Yildirim SE, Buyukserbetci G, Yildirim T, Sackes M, Esmeli F.

Biomedicines · 2025-02-05

DOI: 10.3390/biomedicines13020363PMID: 40002776

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Wei D, Freydenzon A, Guinebretiere O, Zaidi K, Yang F, Ye W, Hammar N, Modig K, Wray NR, Feychting M, Hamieh N, Ventelou B, Lekens B, Gantzer L, Durrleman S, McRae A, Couvy-Duchesne B, Fang F, Nedelec T, LeMeReND consortium.

EBioMedicine · 2025-02-05

DOI: 10.1016/j.ebiom.2025.105585PMID: 39914266

A single-cell transcriptome analysis reveals astrocyte heterogeneity and identifies CHI3L1 as a diagnostic biomarker in Parkinson's disease

Gong Z, Guo D, Lin Y, Liu Z, Lv M, Liu X, Yao Y, Wang S, Wang Y, Wang Z.

Heliyon · 2025-02-01

A systematic review of the effectiveness of digital cognitive assessments of cognitive impairment in Parkinson's disease.

Craig SN, Dempster M, Curran D, Cuddihy AM, Lyttle N.

Appl Neuropsychol Adult · 2025-02-01

DOI: 10.1080/23279095.2025.2454983PMID: 39891618

Parkinsonism in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: Clinical Features and Biomarkers.

Chen CH, Wang TW, Cheng YW, Chu YT, Cheng MF, Chen YF, Lin CH, Tang SC.

J Stroke · 2025-01-31

DOI: 10.5853/jos.2024.03944PMID: 39916462

Epigenetic Biomarkers Driven by Environmental Toxins Associated with Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the United States: A Systematic Review.

Newell ME, Aravindan A, Babbrah A, Halden RU.

Toxics · 2025-01-31

DOI: 10.3390/toxics13020114PMID: 39997929

Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson's disease.

Silva-Rodríguez J, Labrador-Espinosa MÁ, Castro-Labrador S, Muñoz-Delgado L, Franco-Rosado P, Castellano-Guerrero AM, Macías-García D, Jesús S, Adarmes-Gómez AD, Carrillo F, Martín-Rodríguez JF, García-Solís D, Roldán-Lora F, Mir P, Grothe MJ.

Eur J Nucl Med Mol Imaging · 2025-01-31

DOI: 10.1007/s00259-025-07070-zPMID: 39888421

Plasma extracellular vesicle neurofilament light chain as the biomarkers of the progression of Parkinson's disease.

Hong CT, Chung CC, Hsieh YC, Chan L.

Biomol Biomed · 2025-01-30

DOI: 10.17305/bb.2024.11502PMID: 39652080

Evaluation of compliance and accuracy in Parkinson's disease motor symptom tracking: a comparative study of digital and traditional paper diaries using a smartphone application (MyParkinson's).

Durmaz Celik N, Yaman Kula A, Murat N, Kuzu Kumcu M, Topal A, Özkan S.

Front Neurol · 2025-01-29

DOI: 10.3389/fneur.2025.1522721PMID: 39944543

Motor evoked potentials as a side effect biomarker for deep brain stimulation programming

Testini P, Wang A, Cole E, Miocinovic S.

· 2025-01-27

DOI: 10.1101/2025.01.24.25320924

Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes

Hannaway N, Zarkali A, Bhome R, Dobreva I, Thomas GE, Veleva E, Gorostiaga Belio I, Tucker K, Heslegrave A, Zetterberg H, Weil RS.

· 2025-01-27

DOI: 10.1101/2025.01.24.634687